Biotech Amyris Raises Q1 Guidance, Closes On Givaudan Deal
Executive Summary
Emeryville, Calif.-based synthetic biotechnology firm Amyris Inc. is raising its first quarter revenue guidance 12% to $56m as its new Brazilian biomanufacturing facility is delivering product at target. The firm also reports it has closed on its $500m deal with Givaudan SA.